Ani Pharmaceuticals (ANIP) EV to EBITDA (2013 - 2026)

Ani Pharmaceuticals has disclosed EV to EBITDA across 14 years of filings, most recently posting 39.9 for Q2 2026.

• In Q2 2026, EV to EBITDA fell 55.25% year-over-year to 39.9; the TTM figure through Jun 2026 stood at 10.74 (down 86.83% YoY), while the FY2025 annual figure was 12.42, down 90.3% from the prior year.
• EV to EBITDA came in at 39.9 for Q2 2026 at Ani Pharmaceuticals, up from 38.98 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 357.58 in Q4 2022 to a low of 233.43 in Q4 2024.
• Average EV to EBITDA over 5 years is 46.61, with a median of 51.12 recorded in 2025.
• Year-over-year, EV to EBITDA jumped 1885.39% in 2022 and sank 270.29% in 2024.
• Over 5 years, EV to EBITDA stood at 357.58 in 2022, then plunged by 61.66% to 137.08 in 2023, then slumped by 270.29% to 233.43 in 2024, then jumped by 118.36% to 42.85 in 2025, then fell by 6.89% to 39.9 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 39.9 in Q2 2026, 38.98 in Q1 2026, and 42.85 in Q4 2025.